KalVista Pharmaceuticals (NASDAQ:KALV) Rating Increased to Strong-Buy at Citizens Jmp

Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV - Free Report) to a strong-buy rating in a research note issued to investors on Friday morning,Zacks.com reports.

KALV has been the subject of several other reports. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Bank of America initiated coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $22.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $23.80.

KalVista Pharmaceuticals Trading Up 1.6 %

Shares of KalVista Pharmaceuticals stock traded up $0.14 during trading on Friday, hitting $8.91. The stock had a trading volume of 347,522 shares, compared to its average volume of 249,966. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.88. The firm has a market cap of $440.33 million, a price-to-earnings ratio of -2.45 and a beta of 0.86. The business's 50-day moving average is $8.83 and its 200 day moving average is $10.90.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. As a group, equities analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares of the company's stock, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company's stock, valued at $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock worth $304,086 over the last three months. Company insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its position in KalVista Pharmaceuticals by 68.1% during the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock valued at $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $634,000. Vestal Point Capital LP lifted its stake in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company's stock worth $46,320,000 after acquiring an additional 1,700,000 shares during the period. Barclays PLC boosted its holdings in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after acquiring an additional 54,257 shares in the last quarter. Finally, Readystate Asset Management LP bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).